The Oncologist
IUC26661-86 Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide - A single centre study
Abstract Background Apalutamide, in combination with androgen deprivation therapy (ADT), is used to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, real-world evidence describing its effectiveness and tolerability remains limited. This study aimed to assess outcomes in mHSPC patients treated with apalutamide at a single centre. The primary objective was to evaluate treatment-related adverse events. Secondary objectives include overall survival, prostate-specific antigen (PSA) and …